Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 5, 2009, Pages 2089-2099

  Swenson, Dana L ^a,c   Warfield, Kelly L ^a   Warren, Travis K ^a   Lovejoy, Candace ^b   Hassinger, Jed N ^b   Ruthel, Gordon ^a   Blouch, Robert E ^b   Moulton, Hong M ^b   Weller, Dwight D ^b   Iversen, Patrick L ^b   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b AVI BIOPHARMA INC   (United States)

^c Integrated BioTherapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; EBOV VP24 AUG; MARV VP24 AUG; MESSENGER RNA; MORPHOLINE DERIVATIVE; OLIGOMER; PIPERAZINE; UNCLASSIFIED DRUG; VIRUS PROTEIN; VP24 5' TERMINUS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; VP24 AUG 3' TERMINUS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; VP24 AUG 5' TERMINUS PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; VP24 AUG PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; VP24 AUG+4 PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL FREE SYSTEM; CHEMICAL MODIFICATION; CONJUGATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; EBOLA VIRUS; FEMALE; GENE CONSTRUCT; GENE EXPRESSION; GENE SEQUENCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA TRANSLATION; START CODON; STRUCTURE ACTIVITY RELATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EBOLAVIRUS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MICE; MICE, INBRED C57BL; MORPHOLINES; OLIGONUCLEOTIDES, ANTISENSE; RABBITS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME; VERO CELLS; VIRUS REPLICATION;

EID: 63449099709     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00936-08     Document Type: Article

References (42)

1. Abes, R., A. A. Arzumanov, H. M. Moulton, S. Abes, G. D. Ivanova, P. L. Iversen, M. J. Gait, and B. Lebleu. 2007. Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem. Soc. Trans. 35:775-779. (Pubitemid 47310366)
2. Abes, S., H. M. Moulton, P. Clair, P. Prevot, D. S. Youngblood, R. P. Wu, P. L. Iversen, and B. Lebleu. 2006. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J. Control. Release 116:304-313.
3. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651-661. (Pubitemid 28397211)
4. Deas, T. S., C. J. Bennett, S. A. Jones, M. Tilgner, P. Ren, M. J. Behr, D. A. Stein, P. L. Iversen, L. D. Kramer, K. A. Bernard, and P. Y. Shi. 2007. In vitro resistance selection and in vivo efficacy of morpholino oligomers against West Nile virus. Antimicrob. Agents Chemother. 51:2470-2482.
5. Deas, T. S., I. Binduga-Gajewska, M. Tilgner, P. Ren, D. A. Stein, H. M. Moulton, P. L. Iversen, E. B. Kauffman, L. D. Kramer, and P. Y. Shi. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79:4599-4609. (Pubitemid 40464211)
6. Dolnik, O., L. Kolesnikova, and S. Becker. 2008. Filoviruses: interactions with the host cell. Cell. Mol. Life Sci. 65:756-776.
7. Enterlein, S., K. L. Warfield, D. L. Swenson, D. A. Stein, J. L. Smith, C. S. Gamble, A. D. Kroeker, P. L. Iversen, S. Bavari, and E. Muhlberger. 2006. VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50:984-993. (Pubitemid 43327804)
8. Feldmann, H., S. M. Jones, H. Schnittler, and T. Geisbert. 2005. Therapy and prophylaxis of Ebola virus infections. Curr. Opin. Investig. Drugs 6:823-830.
9. Ge, Q., M. Pastey, D. Kobasa, P. Puthavathana, C. Lupfer, R. K. Bestwick, P. L. Iversen, J. Chen, and D. A. Stein. 2006. Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers. Antimicrob. Agents Chemother. 50:3724-3733. (Pubitemid 44684887)
10. Geisbert, T. W., and L. E. Hensley. 2004. Ebolavirus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev. Mol. Med. 6:1-24.
11. Geisbert, T. W., L. E. Hensley, T. Larsen, H. A. Young, D. S. Reed, J. B. Geisbert, D. P. Scott, E. Kagan, P. B. Jahrling, and K. J. Davis. 2003. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163:2347-2370. (Pubitemid 37466478)
12. Gibb, T. R., M. Bray, T. W. Geisbert, K. E. Steele, W. M. Kell, K. J. Davis, and N. K. Jaax. 2001. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125:233-242. (Pubitemid 34023736)
13. Han, Z., H. Boshra, J. O. Sunyer, S. H. Zwiers, J. Paragas, and R. N. Harty. 2003. Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J. Virol. 77:1793-1800. (Pubitemid 36109991)
14. Hart, M. K. 2003. Vaccine research efforts for filoviruses. Int. J. Parasitol. 33:583-595. (Pubitemid 36638539)
15. Iversen, P. L. 2001. Phosphorodiamidate morpholino oligomers, p. 375-389. In S. T. Crooke (ed.), Antisense drug technology. Marcel Dekker, Inc., New York, NY.
16. Iversen, P. L. 2001. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3:235-238. (Pubitemid 32624571)
17. Jahrling, P. B., T. W. Geisbert, J. B. Geisbert, J. R. Swearengen, M. Bray, N. K. Jaax, J. W. Huggins, J. W. LeDuc, and C. J. Peters. 1999. Evaluation of immune globulin and recombinant interferon-alpha2b for treatment of experimental Ebolavirus infections. J. Infect. Dis. 179(Suppl 1):S224-S234. (Pubitemid 29091406)
18. Kinney, R. M., C. Y. Huang, B. C. Rose, A. D. Kroeker, T. W. Dreher, P. L. Iversen, and D. A. Stein. 2005. Inhibition of dengue virus serotypes 1 to 4 in Vero cell cultures with morpholino oligomers. J. Virol. 79:5116-5128. (Pubitemid 40464261)
19. Kuhn, J. H., S. R. Radoshitzky, A. C. Guth, K. L. Warfield, W. Li, M. J. Vincent, J. S. Towner, S. T. Nichol, S. Bavari, H. Choe, M. J. Aman, and M. Farzan. 2006. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a shared receptor J. Biol. Chem. 281:15951-15958. (Pubitemid 43848488)
20. Lebleu, B., H. M. Moulton, R. Abes, G. D. Ivanova, S. Abes, D. A. Stein, P. L. Iversen, A. A. Arzumanov, and M. J. Gait. 2008. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 60:517-529.
21. Moulton, H. M., S. Fletcher, B. W. Neuman, G. McClorey, D. A. Stein, S. Abes, S. D. Wilton, M. J. Buchmeier, B. Lebleu, and P. L. Iversen. 2007. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem. Soc. Trans. 35:826-828. (Pubitemid 47310377)
22. Moulton, H. M., M. H. Nelson, S. A. Hatlevig, M. T. Reddy, and P. L. Iversen. 2004. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug. Chem. 15:290-299. (Pubitemid 38365188)
23. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academy Press, Washington, DC.
24. Nelson, M. H., D. A. Stein, A. D. Kroeker, S. A. Hatlevig, P. L. Iversen, and H. M. Moulton. 2005. Arginine-rich peptide conjugation to morpholino oligomers: effects on antisense activity and specificity. Bioconjug. Chem. 16:959-966. (Pubitemid 41026180)
25. Neuman, B. W., D. A. Stein, A. D. Kroeker, M. J. Churchill, A. M. Kim, P. Kuhn, P. Dawson, H. M. Moulton, R. K. Bestwick, P. L. Iversen, and M. J. Buchmeier. 2005. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers. J. Virol. 79:9665-9676. (Pubitemid 41022309)
26. Neuman, B. W., D. A. Stein, A. D. Kroeker, A. D. Paulino, H. M. Moulton, P. L. Iversen, and M. J. Buchmeier. 2004. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth. J. Virol. 78:5891-5899. (Pubitemid 38661677)
27. Noda, T., P. Halfmann, H. Sagara, and Y. Kawaoka. 2007. Regions in Ebolavirus VP24 that are important for nucleocapsid formation. J. Infect. Dis. 196(Suppl. 2):S247-S250.
28. Patel, D., T. Opriessnig, D. A. Stein, P. G. Halbur, X. J. Meng, P. L. Iversen, and Y. J. Zhang. 2008. Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication. Antivir. Res. 77:95-107.
29. Reid, S. P., C. Valmas, O. Martinez, F. M. Sanchez, and C. F. Basler. 2007. Ebolavirus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 81:13469-13477. (Pubitemid 350252964)
30. Smith, A. W., P. L. Iversen, P. D. O'Hanley, D. E. Skilling, J. R. Christensen, S. S. Weaver, K. Longley, M. A. Stone, S. E. Poet, and D. O. Matson. 2008. Virus-specific antiviral treatment for controlling severe and fatal outbreaks of feline calicivirus infection. Am. J. Vet. Res. 69:23-32.
31. Stein, D. A., D. E. Skilling, P. L. Iversen, and A. W. Smith. 2001. Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 11:317-325. (Pubitemid 33070090)
32. Summerton, J., and D. Weller. 1997. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7:187-195.
33. Towner, J. S., J. Paragas, J. E. Dover, M. Gupta, C. S. Goldsmith, J. W. Huggins, and S. T. Nichol. 2005. Generation of eGFP expressing recombinant Zaire Ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332:20-27. (Pubitemid 40127226)
34. Warfield, K. L., J. G. Perkins, D. L. Swenson, E. M. Deal, C. M. Bosio, M. J. Aman, W. M. Yokoyama, H. A. Young, and S. Bavari. 2004. Role of natural killer cells in innate protection against lethal Ebolavirus infection. J. Exp. Med. 200:169-179. (Pubitemid 38982176)
35. Warfield, K. L., D. L. Swenson, G. G. Olinger, D. K. Nichols, W. D. Pratt, R. Blouch, D. A. Stein, M. J. Aman, P. L. Iversen, and S. Bavari. 2006. Gene-specific countermeasures against Ebolavirus based on antisense phosphorodiamidate morpholino oligomers. PLoS Pathog. 2:5-13.
36. Watanabe, S., T. Noda, P. Halfmann, L. Jasenosky, and Y. Kawaoka. 2007. Ebolavirus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J. Infect. Dis. 196(Suppl. 2):S284-S290.
37. Weller, D. D., and J. N. Hassinger. 2008. Oligonucleotide analogs having cationic intersubunit linkages. Publication no. WO/2008/03612. World Intellectual Property Organization, Geneva, Switzerland.
38. World Health Organization. 2008. Outbreak news. Ebola haemorrhagic fever, Uganda - end of the outbreak. Wkly. Epidemiol. Rec. 83:89-90.
39. Wu, R. P., D. S. Youngblood, J. N. Hassinger, C. E. Lovejoy, M. H. Nelson, P. L. Iversen, and H. M. Moulton. 2007. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res. 35:5182-5191. (Pubitemid 47394201)
40. Youngblood, D. S., S. A. Hatlevig, J. N. Hassinger, P. L. Iversen, and H. M. Moulton. 2007. Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug. Chem. 18:50-60. (Pubitemid 46145994)
41. Yuan, J., D. A. Stein, T. Lim, D. Qiu, S. Coughlin, Z. Liu, Y. Wang, R. Blouch, H. M. Moulton, P. L. Iversen, and D. Yang. 2006. Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J. Virol. 80:11510-11519.
42. Zhang, Y. J., K. Y. Wang, D. A. Stein, D. Patel, R. Watkins, H. M. Moulton, P. L. Iversen, and D. O. Matson. 2007. Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers. Antivir. Res. 73:12-23. (Pubitemid 46080474)